{{Rsnum
|rsid=1714984
|Gene=MYOCD
|Chromosome=17
|position=12714384
|Orientation=plus
|GMAF=0.3783
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=MYOCD
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 4.4 | 38.9 | 56.6
| HCB | 6.6 | 47.4 | 46.0
| JPT | 10.6 | 50.4 | 38.9
| YRI | 53.7 | 42.2 | 4.1
| ASW | 28.1 | 64.9 | 7.0
| CHB | 6.6 | 47.4 | 46.0
| CHD | 15.6 | 41.3 | 43.1
| GIH | 16.8 | 42.6 | 40.6
| LWK | 61.8 | 34.5 | 3.6
| MEX | 10.3 | 34.5 | 55.2
| MKK | 40.4 | 51.3 | 8.3
| TSI | 4.9 | 29.4 | 65.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=20560679
|Title=Response to Methadone Maintenance Treatment is Associated with the MYOCD and GRM6 Genes
}}

{{PMID Auto
|PMID=18195715
|Title=Genotype patterns that contribute to increased risk for or protection from developing heroin addiction.
|OA=1
}}

{{PMID Auto
|PMID=18725235
|Title=Bidirectional translational research: Progress in understanding addictive diseases.
|OA=1
}}

{{PMID Auto
|PMID=19155191
|Title=Opiate and cocaine addiction: from bench to clinic and back to the bench.
|OA=1
}}

{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}